Skip to content
Screener

Net Change in Cash at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$817M+89.6%
Danaher logo
DanaherDHR
-$1.35B-240%
Azenta logo
AzentaAZTA
-$44.62M
Agilent Technologies logo
Agilent TechnologiesA
$49M+158%
Illumina logo
IlluminaILMN
-$49M+72.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$51.45M-1,849%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Six months ended March 31, 2026Six months ended March 31, 2025
Proceeds from issuance under employee stock purchase plan2,3572,429
Repurchases of common stock for income tax withholding(10)(11)
Net cash provided by financing activities$4,436$21,140
Effect of exchange rates on cash, cash equivalents and restricted cash$3$51
Net decrease in cash, cash equivalents, and restricted cash(60,573)(16,185)
Cash, cash equivalents, and restricted cash at beginning of period185,425229,132
Cash, cash equivalents, and restricted cash at end of period$124,852$212,947
Supplemental disclosure of cash flow information

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's net change in cash?
Twist Bioscience Corporation (TWST) reported net change in cash of -$26.13M in Q1 2026.
How has Twist Bioscience Corporation's net change in cash changed year-over-year?
Twist Bioscience Corporation's net change in cash decreased by 135.2% year-over-year, from -$11.11M to -$26.13M.
What is the long-term trend for Twist Bioscience Corporation's net change in cash?
Over 3 years (2021 to 2025), Twist Bioscience Corporation's net change in cash has grown at a -51.5% compound annual growth rate (CAGR), from $382.56M to -$43.71M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Twist Bioscience Corporation's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude